Coronavirus (COVID-19): visiting The Royal Marsden suspended

Coronavirus (COVID-19) latest: Visiting The Royal Marsden is still suspended, but we want to reassure our patients, their families and anyone worried about cancer during this difficult time that we are still delivering treatment - the hospital is open. Please see more information here about how we are keeping everyone safe.

NHS Healthcare Providers

We offer extensive cancer genomic testing specific to solid tumours and haematological malignancies.

What is cancer genomic testing? 

In the new Genomic Medicine Service many more people with cancer are now being offered genomic testing as increasingly treatment can be personalised depending on the genomic changes seen in the tumour.  The NHS National Genomic Test Directory for solid tumours and haematological malignancies specifies which genomic tests are commissioned by the NHS in England, the technology by which they are available, and the patients who will be eligible to access to a test, details of which can be found here https://www.england.nhs.uk/publication/national-genomic-test-directories/ 

We provide a comprehensive testing repertoire to support the diagnosis and prognosis of haematological malignancies, for full test repertoire click here

We have NGS panels that cover the following tumour sites: 

  • Adrenal
  • Bile duct
  • Bladder
  • Breast
  • Colorectal
  • Gastrointestinal
  • Haematological
  • Head & Neck
  • Liver
  • Lung / Mesothelioma 
  • Neurological
  • Ovarian
  • Pancreatic
  • Prostate
  • Renal 
  • Salivary gland
  • Sarcoma
  • Skin / Melanoma
  • Thyroid

Tests ordered off the directory will be run on an appropriate UKAS accredited (ISO 15189:2012) Next Generation Sequencing (NGS) or Fluorescence In Situ Hybridisation (FISH) gene panels, and results specific to that test will be reported and evaluated for clinical significance by our experienced HCPC registered Clinical Scientists. 

For details of the genes included in the RMH NGS panels for solid tumours and haematological malignancies, including NTRK fusions click here.

For details on how to refer please contact us

For further information on sample requirements and expected turnaround times please see our Service Specification guide.